Literature DB >> 7861195

A review of the microbiology of amoxycillin/clavulanic acid over the 15 year period 1978-1993.

G N Rolinson1.   

Abstract

A review of the published literature over the period 1978-1993 was undertaken to assess any changes in the prevalence of beta-lactamase-producing bacterial pathogens and also any changes in the susceptibility in these pathogens to amoxycillin/clavulanate. The review has involved the examination of over 1500 publications. The review shows that in general there has been an increase in the frequency of beta-lactamase-producing pathogens resistant to ampicillin and amoxycillin but there is no evidence for any significant increase in resistance to amoxycillin/clavulanate over the period of the review.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7861195     DOI: 10.1080/1120009x.1994.11741165

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  9 in total

Review 1.  New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review.

Authors:  Amparo Sánchez Navarro
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin).

Authors:  I Simpson; J Durodie; S Knott; B Shea; J Wilson; K Machka
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

3.  Comparative Assessment of Antimicrobial Efficacy of Different Antibiotic Coated Gutta-Percha Cones on Enterococcus faecalis An Invitro Study.

Authors:  Vardhaman Mulchand Jain; Gundabaktha Nagappa Karibasappa; Arun Suresh Dodamani; Prashanth Kumar Vishwakarma; Gaurao Vasant Mali
Journal:  J Clin Diagn Res       Date:  2016-09-01

Review 4.  Beta-lactam/beta-lactamase inhibitor combinations: development, antibacterial activity and clinical applications.

Authors:  R Sutherland
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553

5.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Gengrong Lin; David Felmingham; Christine Dencer; Laura Koeth; Mendel E Singer; Caryn E Good
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

7.  In vitro activity and in vivo efficacy of clavulanic acid against Acinetobacter baumannii.

Authors:  Alejandro Beceiro; Rafael López-Rojas; Juan Domínguez-Herrera; Fernando Docobo-Pérez; Germán Bou; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

8.  In vitro activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin.

Authors:  J Prieto; L Aguilar; M J Giménez; D Toro; M L Gómez-Lus; R Dal-Ré; I P Balcabao
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

9.  Overproduction of Clavulanic Acid by UV Mutagenesis of Streptomyces clavuligerus.

Authors:  Hassan Korbekandi; Parisa Darkhal; Zohreh Hojati; Daryoush Abedi; Javad Hamedi; Meraj Pourhosein
Journal:  Iran J Pharm Res       Date:  2010       Impact factor: 1.696

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.